BioSyent (CVE:RX) Share Price Passes Above Fifty Day Moving Average – Here’s What Happened

BioSyent Inc. (CVE:RX) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of C$14.35 and traded as high as C$15.44. BioSyent shares last traded at C$15.35, with a volume of 2,359 shares trading hands.

Analysts Set New Price Targets

Separately, Bloom Burton raised BioSyent from a “moderate buy” rating to a “strong-buy” rating in a report on Friday, November 21st. One analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Strong Buy”.

BioSyent Price Performance

The company’s 50-day moving average price is C$14.35 and its two-hundred day moving average price is C$12.63. The company has a debt-to-equity ratio of 2.24, a current ratio of 5.06 and a quick ratio of 6.91. The company has a market capitalization of C$176.48 million, a P/E ratio of 20.52 and a beta of 0.93.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.